Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 188-196

  Kraal, K C J M ^a,f   Bleeker, G M ^b   van Eck Smit, B L F ^c   van Eijkelenburg, N K A ^f   Berthold, F ^d   van Noesel, M M ^e,f   Caron, H N ^a   Tytgat, G A M ^a,f  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NWZ Alkmaar ^*  (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f Department of Radiation Oncology   (Netherlands)

Author keywords

131I MIBG (meta iodobenzylguanidine); NBL (neuroblastoma)

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; MYELOABLATIVE AGENT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; MALE; MULTICENTER STUDY; NEUROBLASTOMA; NEUTROPHIL; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ABDOMINAL NEOPLASMS; AUTOTRANSPLANTATION; CANCER STAGING; FEASIBILITY STUDY; INDUCTION CHEMOTHERAPY; INFANT; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; STEM CELL TRANSPLANTATION; SURGERY; THORACIC NEOPLASMS; TIME FACTOR;

3-IODOBENZYLGUANIDINE; ABDOMINAL NEOPLASMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; INFANT, NEWBORN; MALE; MYELOABLATIVE AGONISTS; NEOPLASM STAGING; NEUROBLASTOMA; PILOT PROJECTS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURGICAL PROCEDURES, OPERATIVE; THORACIC NEOPLASMS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 85015399036     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.12.013     Document Type: Article

References (29)

1. [1] Gurney, J.G., Davis, S., Severson, R.K., Fang, J.Y., Ross, J.A., Robison, L.L., Trends in cancer incidence among children in the U.S. Cancer 78:3 (1996 August 1), 532–541.
2. [2] Simon, T., Berthold, F., Borkhardt, A., Kremens, B., De, C.B., Hero, B., Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 56:4 (2011 April), 578–583.
3. [3] Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:16 (1999 October 14), 1165–1173.
4. [4] Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:14 (2010 September 30), 1324–1334.
5. [5] Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6:9 (2005 September), 649–658.
6. [6] Suc, A., Lumbroso, J., Rubie, H., Hattchouel, J.M., Boneu, A., Rodary, C., et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77:4 (1996 February 15), 805–811.
7. [7] Messina, J.A., Cheng, S.C., Franc, B.L., Charron, M., Shulkin, B., To, B., et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 47:7 (2006 December), 865–874.
8. [8] Matthay, K.K., Edeline, V., Lumbroso, J., Tanguy, M.L., Asselain, B., Zucker, J.M., et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:13 (2003 July 1), 2486–2491.
9. [9] Hattner, R.S., Huberty, J.P., Engelstad, B.L., Gooding, C.A., Ablin, A.R., Localization of m-iodo(131I)benzylguanidine in neuroblastoma. AJR Am J Roentgenol 143:2 (1984 August), 373–374.
10. [10] Klingebiel, T., Berthold, F., Treuner, J., Schwabe, D., Fischer, M., Feine, U., et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol 19:2 (1991), 84–88.
11. [11] Matthay, K.K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.C., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:9 (2007 March 20), 1054–1060.
12. [12] Hutchinson, R.J., Sisson, J.C., Miser, J.S., Zasadny, K.R., Normolle, D.P., Shulkin, B.L., et al. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 35:4 (1991 October), 237–240.
13. [13] Lashford, L.S., Lewis, I.J., Fielding, S.L., Flower, M.A., Meller, S., Kemshead, J.T., et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10:12 (1992 December), 1889–1896.
14. [14] Lumbroso, J., Hartmann, O., Schlumberger, M., Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. “Societe Francaise d'Oncologie Pediatrique” and nuclear medicine co-investigators. J Nucl Biol Med 35:4 (1991 October), 220–223.
15. [15] Matthay, K.K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R.S., Ablin, A., et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:1 (1998 January), 229–236.
16. [16] Voute, P.A., Hoefnagel, C.A., de, K.J., Valdes, O.R., Bakker, D.J., van de Kleij, A.J., Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 366 (1991), 439–445.
17. [17] Johnson, K., McGlynn, B., Saggio, J., Baniewicz, D., Zhuang, H., Maris, J.M., et al. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer 57:7 (2011 December 15), 1124–1129.
18. [18] Wilson, J.S., Gains, J.E., Moroz, V., Wheatley, K., Gaze, M.N., A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 50:4 (2014 March), 801–815.
19. [19] Brodeur, G.M., Seeger, R.C., Barrett, A., Berthold, F., Castleberry, R.P., D'Angio, G., et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:12 (1988 December), 1874–1881.
20. [20] Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L., Castel, V., Castelberry, R.P., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:8 (1993 August), 1466–1477.
21. [21] van Santen, H.M., de, K.J., van Eck, B.L., de Vijlder, J.J., Vulsma, T., High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 94:7 (2002 April 1), 2081–2089.
22. [22] Matthay, K.K., Shulkin, B., Ladenstein, R., Michon, J., Giammarile, F., Lewington, V., et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) task force. Br J Cancer 102:9 (2010 April 27), 1319–1326.
23. [23] Pearson, A.D., Pinkerton, C.R., Lewis, I.J., Imeson, J., Ellershaw, C., Machin, D., High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). Lancet Oncol 9:3 (2008 Mar), 247–256.
24. [24] Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Klingebiel, T., et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer, 11, 2011 Jan 18, 21, 10.1186/1471-2407-11-21.
25. [25] Kreissman, S.G., Seeger, R.C., Matthay, K.K., London, W.B., Sposto, R., Grupp, S.A., et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:10 (2013 July), 999–1008.
26. [26] DuBois, S.G., Messina, J., Maris, J.M., Huberty, J., Glidden, D.V., Veatch, J., et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22:12 (2004 June 15), 2452–2460.
27. [27] Goldberg, S.S., DeSantes, K., Huberty, J.P., Price, D., Hasegawa, B.H., Reynolds, C.P., et al. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 30:6 (1998 June), 339–346.
28. [28] Yanik, G.A., Levine, J.E., Matthay, K.K., Sisson, J.C., Shulkin, B.L., Shapiro, B., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:8 (2002 April 15), 2142–2149.
29. [29] Pradhan, K.R., Johnson, C.S., Vik, T.A., Sender, L.S., Kreissman, S.G., A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer 46:7 (2006 June), 793–802.